Moreover, the comparison of mouse DEGs with human melanoma patients (n = 21 anti-PD1 therapy responder) and (n = 17 non-responder) reveals eight common genes associated with ALKBH5-deficiency and eleven common genes with FTO-deficiency, indicating ‘conserved’ and potential targets of ALKBH5 and FTO in mouse as well as human receiving anti-PD1 therapy. This evidence concerns the gene FTO and melanoma.